The global anti-biofilm wound dressing market was surpassed at USD 714.80 million in 2022 and is expected to hit around USD 1,794.22 million by 2032, growing at a CAGR of 9.64% from 2023 to 2032.
Key Pointers
Report Coverage | Details |
Market Size in 2022 | USD 714.80 million |
Revenue Forecast by 2032 | USD 1,794.22 million |
Growth rate from 2023 to 2032 | CAGR of 9.64% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Covered | ConvaTec Inc.; Smith & Nephew PLC; Urgo Medical; Coloplast; 3M; Mölnlycke Health Care AB; Imbed Biosciences; Next Science; B. Braun Melsungen AG; Lohmann & Rauscher |
The increasing incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases is anticipated to increase the incidence rate of chronic and acute wounds across the globe. Factors such as antimicrobial resistance, unhealthy & sedentary lifestyles, and tobacco & alcohol consumption are contributing to the rising prevalence of non-communicable diseases. For instance, according to the CDC’s National Diabetes Statistics report of 2020, the number of diabetes patients has increased to an estimated 34.2 million, which comprises about 10.5% of the total population. According to a similar report, an estimated 26.8 million people have been diagnosed with diabetes, whereas 7.3 million people had diabetes and were yet to be diagnosed.
Chronic wounds and surgical wounds all have a deleterious impact on wound recovery. The growing geriatric population, rising prevalence of traumatic wounds, an increasing number of surgeries, and rising incidence of illnesses, such as obesity & diabetes, are among the factors contributing to the rising prevalence of chronic wounds over the last decade.
According to the U.S. CDC, 6 in 10 adults are suffering from a chronic disease and 4 in 10 adults are suffering from two or more chronic diseases in the U.S. Furthermore, chronic diseases are the leading cause of disability & death and a key contributor to the country’s USD 3.5 trillion annual healthcare costs. As a result of the rising prevalence of chronic conditions, the number of surgeries being performed has increased. Wound dressing products such as silver-based wound dressing are increasingly being used to prevent surgical site infections.
Most surgical wounds after cancer surgery are generally large in size & deep, producing exudate that requires regular management. Anti-biofilm wound dressing products such as silver, and iodine-based wound dressings help to manage large wounds, thus, reducing the risk of infection. Therefore, the rising incidence of chronic diseases is expected to boost the demand for the products, thereby propelling the growth of the market over the forecast period.
Increasing incidence of burns, trauma events, and road accidents across the globe is anticipated to drive market growth. For instance, as per Association for Safe International Road Travel, approximately, 1.35 million people die every year in a road crash, whereas on average 3,700 people lose their lives every day on the road. Thus, the rising number of accidents is expected to boost the demand for enzymatic wound debridement products, which is expected to lead to considerable growth in the industry over the forecast period.
Market Segmentations: